Draft scoping review: melanocortin receptor agonists
Consultation on the draft scoping review of melanocortin receptor agonists, which maps the evidence across approved indications and the uses for which these compounds are supplied outside a regulated route. The review is scoping because the approved and…
§1Consultation and window
§1.1Window
- Opened
- 27 October 2025
- Closed
- 8 December 2025
- Duration
- 42 days
- Status
- Closed — the disposition is published
- Document under consultation
- Synthesis: Melanocortin receptor agonists: approved indications and supplied uses
- Submissions received
- 11
§1.2Consultation questions
The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.
- Is the separation between approved indications and supplied uses maintained consistently throughout the document?
- Is the pigmentary and dermatological safety evidence characterised correctly as to its source and its limits?
- Does the review state clearly enough that evidence for one melanocortin receptor subtype is not evidence for another?
§1.3How a submission is handled
- Every submission is signed. The Institute publishes no anonymous submission.
- Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
- A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
- Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
- There is no voting, no reputation score, no reply thread and no editing after receipt.
§1.4Outcome
The review was amended before ratification. Receptor subtype selectivity is now stated for every compound in the map, and a standing statement records that an approval for one indication is not evidence for a different use of the same compound.
The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.